BACKGROUND: The active metabolites of tenofovir (TFV) and emtricitabine (FTC) in peripheral blood mononuclear cells (PBMCs) have been used as markers of long-term antiretroviral (ARV) adherence. However, the process of isolating PBMCs is expensive, complex, and not feasible in many settings. We compared concentrations of TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in the upper layer packed cells (ULPCs) obtained after whole blood centrifugation to isolated PBMCs as a possible alternative marker of adherence. METHODS: Ten HIV+ adults with HIV RNA <50 copies/mL on a TDF/FTC-containing regimen provided 5 paired PBMC and ULPC samples over 6 hours. TFV-DP and FTC-TP concentrations were analyzed by liquid chromatography/mass spectrometry. Partial areas under the curve were calculated using noncompartmental methods and Spearman Rank Correlations (rho) between PBMC and ULPC were determined. RESULTS: The median (25th-75th percentile) concentration of TFV-DP in PBMCs was 143 (103-248) fmol/10(6) cells and in ULPC was 227 (160-394) fmol/10(6) cells (rho = 0.65; P < 0.0001). The concentration of FTC-TP in PBMCs was 6660 (5650-10,000) fmol/10(6) cells and in ULPC was 19.0 (12.0-27.8) fmol/10(6) cells (rho = 0.55; P < 0.0001). Compared to PBMCs, ULPC TFV-DP was 64% higher and FTC-TP was 99.7% lower. ULPC concentrations of TFV-DP and FTC-TP in one additional subject receiving a single dose of TDF/FTC were only 0.05% and 25%, of the other 10 subjects, respectively. CONCLUSIONS: ULPC concentrations significantly correlated with PBMC concentrations. Preliminary single-dose data suggest some discrimination between intermittent versus consistent dosing. ULPC concentrations of TFV-DP and FTC-TP should be further investigated as a simply collected surrogate measure of ARV adherence.
BACKGROUND: The active metabolites of tenofovir (TFV) and emtricitabine (FTC) in peripheral blood mononuclear cells (PBMCs) have been used as markers of long-term antiretroviral (ARV) adherence. However, the process of isolating PBMCs is expensive, complex, and not feasible in many settings. We compared concentrations of TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in the upper layer packed cells (ULPCs) obtained after whole blood centrifugation to isolated PBMCs as a possible alternative marker of adherence. METHODS: Ten HIV+ adults with HIV RNA <50 copies/mL on a TDF/FTC-containing regimen provided 5 paired PBMC and ULPC samples over 6 hours. TFV-DP and FTC-TP concentrations were analyzed by liquid chromatography/mass spectrometry. Partial areas under the curve were calculated using noncompartmental methods and Spearman Rank Correlations (rho) between PBMC and ULPC were determined. RESULTS: The median (25th-75th percentile) concentration of TFV-DP in PBMCs was 143 (103-248) fmol/10(6) cells and in ULPC was 227 (160-394) fmol/10(6) cells (rho = 0.65; P < 0.0001). The concentration of FTC-TP in PBMCs was 6660 (5650-10,000) fmol/10(6) cells and in ULPC was 19.0 (12.0-27.8) fmol/10(6) cells (rho = 0.55; P < 0.0001). Compared to PBMCs, ULPC TFV-DP was 64% higher and FTC-TP was 99.7% lower. ULPC concentrations of TFV-DP and FTC-TP in one additional subject receiving a single dose of TDF/FTC were only 0.05% and 25%, of the other 10 subjects, respectively. CONCLUSIONS: ULPC concentrations significantly correlated with PBMC concentrations. Preliminary single-dose data suggest some discrimination between intermittent versus consistent dosing. ULPC concentrations of TFV-DP and FTC-TP should be further investigated as a simply collected surrogate measure of ARV adherence.
Authors: J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum Journal: Clin Infect Dis Date: 2001-09-05 Impact factor: 9.079
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Trevor Hawkins; Wenoah Veikley; Robert L St Claire; Bill Guyer; Nicole Clark; Brian P Kearney Journal: J Acquir Immune Defic Syndr Date: 2005-08-01 Impact factor: 3.731
Authors: Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant Journal: J Antimicrob Chemother Date: 2010-11-30 Impact factor: 5.790
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: Aaron S Devanathan; John K Fallon; Nicole R White; Amanda P Schauer; Brian Van Horne; Kimberly Blake; Craig Sykes; Martina Kovarova; Lourdes Adamson; Leila Remling-Mulder; Paul Luciw; J Victor Garcia; Ramesh Akkina; Jason R Pirone; Philip C Smith; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Peter L Anderson; Albert Y Liu; Jose R Castillo-Mancilla; Edward M Gardner; Sharon M Seifert; Cricket McHugh; Theresa Wagner; Kayla Campbell; Mary Morrow; Mustafa Ibrahim; Susan Buchbinder; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Paul K Drain; Ashley R Bardon; Jane M Simoni; Tim R Cressey; Pete Anderson; Derin Sevenler; Ayokunle O Olanrewaju; Monica Gandhi; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2020-10 Impact factor: 5.071
Authors: Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson Journal: Contemp Clin Trials Date: 2016-11-09 Impact factor: 2.226
Authors: Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson Journal: AIDS Res Hum Retroviruses Date: 2015-10-15 Impact factor: 2.205